2246-20-0

Upstream product

• 1092-95-1 C₁₉H₂₃NO₂ 
• 1357172-85-0 3-methoxy-17-(2,2,2-trichloroethoxycarbonyl)morphinan-6-spiro-2'-(1',3'-dioxolane) 
• 1372779-45-7 17-cyclopropylmethyl-3-methoxymorphinan-6-spiro-2'-(1',3'-dioxolane) 
• 1043876-55-6 C₂₃H₃₁NO₄ 
• 1069111-48-3 17-cyclopropylmethyl-8,14-dehydro-3-methoxymorphinan-6-spiro-2'-(1',3'-dioxolane) 
• 1227681-13-1 (4bS,9R)-3-methoxy-11-methyl-6-oxo-6,7,8,8a,9,10-hexahydro-5H-9,4b-(epiminoethano)phenanthren-4-yl trifluoromethanesulfonate 
• 50-00-0 formaldehyd 
• 4978-44-3 3-methoxy-6-keto-normorphinan 
• 1612-46-0 7,8-didehydro-3-methoxy-17-methylmorphinan-6-one 
• 76-57-3 codeine 
• 125-29-1 Hydrocodone 
• 847-86-9 (-)-Dihydrothebainon 
• 467-98-1 7,8-didehydro-4-hydroxy-3-methoxy-17-methyl-morphinan-6-one 
• 74924-36-0 dihydrothebainone-4-phenyl ether ethylene glycol ketal 

Relevant academic research and scientific papers

Design and synthesis of novel delta opioid receptor agonists and their pharmacologies

We re-examined the accessory site of the 4,5-epoxymorphinan skeleton by camdas conformational analysis in an effort to deign novel δ opioid receptor antagonists. We synthesized three novel compounds (SN-11, 23 and 28) with a 10-methylene bridge and withou

Novel opiates and antagonists. 5. 7-Carbethoxy-N-(cycloalkylmethyl)-3-hydroxymorphinan-6-ones and -isomorphinan-6-ones

A direct conversion of deoxydihydrothebaine-? (1) to 3-methoxymorphinan-6-one (3Ca) and its trans isomer 3Ta was achieved in excellent yield by the catalytic reduction of 1 in AcOH containing CF3COOH. Treatment of 3Ca or 3Ta with NaH and diethyl carbonate formed the corresponding 7-carbethoxy derivatives 4a which, on O-demethylation, furnished the 3-hydroxy compounds 4b. The analgesic N-methyl compounds 3 were converted to the 17-(cyclopropylmethyl) or 17-(cyclobutylmethyl) derivatives 6-8. Two of these compounds, one in the cis (7Ca) and the other in the trans (7Ta) series, showed mixed agonist/antagonist activity in the pentazocine range.

Synthesis and pharmacological evaluation of aminothiazolomorphinans at the Mu and Kappa opioid receptors

Previous studies with aminothiazolomorphinans suggested that this class of opioid ligands may be useful as a potential pharmacotherapeutic to decrease drug abuse. Novel aminothiazole derivatives of cyclorphan were prepared to evaluate a series of aminothiazolomorphinans with varying pharmacological properties at the κ opioid receptor (KOR) and μ opioid receptor (MOR). This study was focused on exploring the regioisomeric analogs with the aminothiazole on the C-ring of the morphinan skeleton. Receptor binding and [35S] GTPγS binding assays were used to characterize the affinity and pharmacological properties of the aminothiazolomorphinans. Intracranial self-stimulation (ICSS) was used to compare the effects of a representative aminothiazolomorphinan with the morphinan mixed-KOR/MOR agonist butorphan (MCL-101) on brain-stimulation reward.

Synthesis of quinolinomorphinan-4-ol derivatives as δ opioid receptor agonists

The previously reported morphinan derivative SN-28 showed high selectivity and agonist activity for the δ opioid receptor. In the course of examining the structure-activity relationship of SN-28 derivatives, the derivatives with the 4-hydroxy group (SN-24

Rapid access to morphinones: removal of 4,5-ether bridge with Pd-catalyzed triflate reduction

A new synthetic method for the removal of the 4,5-bridged ether moiety of several opioids has been developed. This process offers a faster, simpler synthetic route to obtain the morphinone scaffold in high yields without the need for protection of the ketone moiety.

Synthesis and pharmacological evaluation of 6,7-indolo/thiazolo-morphinans - Further SAR of levorphanol

To further extend the structure-activity relationships of levorphanol, two series of novel morphinans were prepared by incorporation of an indole or aminothiazole fragment to the hexyl ring (ring C) in levorphanol. Such morphinans differed from previously reported ligands in that such indole- or aminothiazole-containing morphinans displayed enhanced binding affinity to the δ opioid receptor, while the affinity to κ and μ receptors was slightly reduced.

7-Methyl-8β-lower alkyl or 7-methyl-8-lower alkyl B/C cis or trans morphinan-6-one compounds and therapeutic method of treating pain employing them

Disclosed are 7-methyl, 8β-lower alkyl and 7 methyl-8-lower alkyl substituted B/C Cis or Trans morphinan-6-one compounds characterized by the structural formula: STR1 Specific compounds, included within the scope of the foregoing general formula wherein R1 is H or methyl, R2 is cyclopropylmethyl or cyclobutylmethyl, R3 is H, methyl, ethyl or n-propyl and R4 is H or methyl are useful as mixed analgesics/narcotic antagonists.